1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Treatments	_	_	NNS	_	_	_	_	_
2	for	_	_	IN	_	_	_	_	_
3	Diabetic	_	_	JJ	_	_	_	_	_
4	Foot	_	_	NN	_	_	_	_	_
5	Ulcers	_	_	NNS	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	strategy	_	_	NN	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	management	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	DFU	_	_	NN	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	introduce	_	_	VB	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	multidisciplinary	_	_	JJ	_	_	_	_	_
16	approach	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	address	_	_	VB	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	multifactorial	_	_	JJ	_	_	_	_	_
21	processes	_	_	NNS	_	_	_	_	_
22	involved	_	_	VBN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	DFUs	_	_	NNP	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	use	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	multi-disciplinary	_	_	JJ	_	_	_	_	_
5	teams	_	_	NNS	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	MDTs	_	_	NNP	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_
9	that	_	_	WDT	_	_	_	_	_
10	include	_	_	VBP	_	_	_	_	_
11	all	_	_	DT	_	_	_	_	_
12	relevant	_	_	JJ	_	_	_	_	_
13	specialties	_	_	NNS	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	i.	_	_	FW	_	_	_	_	_
16	e.	_	_	FW	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	nursing	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	orthopedics	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	plastic	_	_	JJ	_	_	_	_	_
23	surgery	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	vascular	_	_	JJ	_	_	_	_	_
26	surgery	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	nutrition	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	endocrinology	_	_	NN	_	_	_	_	_
32	departments	_	_	NNS	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	has	_	_	VBZ	_	_	_	_	_
35	shown	_	_	VBN	_	_	_	_	_
36	an	_	_	DT	_	_	_	_	_
37	effect	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	decreasing	_	_	VBG	_	_	_	_	_
40	the	_	_	DT	_	_	_	_	_
41	risks	_	_	NNS	_	_	_	_	_
42	associated	_	_	VBN	_	_	_	_	_
43	with	_	_	IN	_	_	_	_	_
44	DFUs	_	_	NN	_	_	_	_	_
45	and	_	_	CC	_	_	_	_	_
46	amputation	_	_	NN	_	_	_	_	_
47	by	_	_	IN	_	_	_	_	_
48	50	_	_	CD	_	_	_	_	_
49	–	_	_	TO	_	_	_	_	_
50	85	_	_	CD	_	_	_	_	_
51	%	_	_	NN	_	_	_	_	_
52	,	_	_	,	_	_	_	_	_
53	lowering	_	_	VBG	_	_	_	_	_
54	costs	_	_	NNS	_	_	_	_	_
55	,	_	_	,	_	_	_	_	_
56	and	_	_	CC	_	_	_	_	_
57	leading	_	_	VBG	_	_	_	_	_
58	to	_	_	TO	_	_	_	_	_
59	a	_	_	DT	_	_	_	_	_
60	better	_	_	JJR	_	_	_	_	_
61	quality	_	_	NN	_	_	_	_	_
62	of	_	_	IN	_	_	_	_	_
63	life	_	_	NN	_	_	_	_	_
64	for	_	_	IN	_	_	_	_	_
65	patients	_	_	NNS	_	_	_	_	_
66	with	_	_	IN	_	_	_	_	_
67	DFUs	_	_	NNP	_	_	_	_	_
68	.	_	_	.	_	_	_	_	_


1	Management	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	DFUs	_	_	NNP	_	_	_	_	_
4	requires	_	_	VBZ	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	correct	_	_	JJ	_	_	_	_	_
7	classification	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	stage	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	severity	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Adequate	_	_	JJ	_	_	_	_	_
2	care	_	_	NN	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	DFUs	_	_	NNP	_	_	_	_	_
5	should	_	_	MD	_	_	_	_	_
6	include	_	_	VB	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	focus	_	_	NN	_	_	_	_	_
9	on	_	_	IN	_	_	_	_	_
10	DM	_	_	NN	_	_	_	_	_
11	control	_	_	NN	_	_	_	_	_
12	as	_	_	RB	_	_	_	_	_
13	well	_	_	RB	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	on	_	_	IN	_	_	_	_	_
16	wound	_	_	NN	_	_	_	_	_
17	care	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	proper	_	_	JJ	_	_	_	_	_
20	infection	_	_	NN	_	_	_	_	_
21	control	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	relieving	_	_	VBG	_	_	_	_	_
24	pressure	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	optimizing	_	_	VBG	_	_	_	_	_
28	blood	_	_	NN	_	_	_	_	_
29	flow	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	basic	_	_	JJ	_	_	_	_	_
3	care	_	_	NN	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	control	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	treatment	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	DFUs	_	_	NNP	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	focused	_	_	VBN	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	management	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	adequate	_	_	JJ	_	_	_	_	_
18	perfusion	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	pressure	_	_	NN	_	_	_	_	_
21	mitigation	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	control	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	infection	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	debridement	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	With	_	_	IN	_	_	_	_	_
2	technological	_	_	JJ	_	_	_	_	_
3	advancement	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	other	_	_	JJ	_	_	_	_	_
6	series	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	therapies	_	_	NNS	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	DFUs	_	_	NNP	_	_	_	_	_
11	have	_	_	VBP	_	_	_	_	_
12	been	_	_	VBN	_	_	_	_	_
13	implemented	_	_	VBN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	such	_	_	JJ	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	development	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	skin	_	_	NN	_	_	_	_	_
21	substitutes	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	negative	_	_	JJ	_	_	_	_	_
24	pressure	_	_	NN	_	_	_	_	_
25	wound	_	_	NN	_	_	_	_	_
26	therapy	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	hyperbaric	_	_	JJ	_	_	_	_	_
29	oxygen	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	creation	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	new	_	_	JJ	_	_	_	_	_
35	wound	_	_	NN	_	_	_	_	_
36	dressings	_	_	NNS	_	_	_	_	_
37	that	_	_	WDT	_	_	_	_	_
38	include	_	_	VBP	_	_	_	_	_
39	growth	_	_	NN	_	_	_	_	_
40	factors	_	_	NNS	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	and	_	_	CC	_	_	_	_	_
43	the	_	_	DT	_	_	_	_	_
44	use	_	_	NN	_	_	_	_	_
45	of	_	_	IN	_	_	_	_	_
46	tissues	_	_	NNS	_	_	_	_	_
47	from	_	_	IN	_	_	_	_	_
48	bioengineering	_	_	NN	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	way	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	treatments	_	_	NNS	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	DPN	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	PAD	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	infections	_	_	NNS	_	_	_	_	_
13	have	_	_	VBP	_	_	_	_	_
14	provided	_	_	VBN	_	_	_	_	_
15	encouraging	_	_	JJ	_	_	_	_	_
16	results	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	4.1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Treatments	_	_	NNS	_	_	_	_	_
2	for	_	_	IN	_	_	_	_	_
3	Diabetic	_	_	JJ	_	_	_	_	_
4	Peripheral	_	_	JJ	_	_	_	_	_


1	Neuropathy	_	_	NN	_	_	_	_	_


1	DPN	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	factor	_	_	NN	_	_	_	_	_
5	that	_	_	WDT	_	_	_	_	_
6	increases	_	_	VBZ	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	risk	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	appearance	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	DFU	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	owing	_	_	VBG	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	loss	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	sensation	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	limb	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	making	_	_	VBG	_	_	_	_	_
27	patients	_	_	NNS	_	_	_	_	_
28	vulnerable	_	_	JJ	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	trauma	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Tight	_	_	JJ	_	_	_	_	_
2	glycemic	_	_	JJ	_	_	_	_	_
3	control	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	primary	_	_	JJ	_	_	_	_	_
7	step	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	main	_	_	JJ	_	_	_	_	_
11	feature	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	DPN	_	_	NN	_	_	_	_	_
14	management	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Normoglycemia	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	more	_	_	RBR	_	_	_	_	_
4	effectively	_	_	RB	_	_	_	_	_
5	restored	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	pancreas	_	_	NN	_	_	_	_	_
9	transplant	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	demonstrated	_	_	VBN	_	_	_	_	_
5	improvement	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	motor	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	sensory	_	_	JJ	_	_	_	_	_
10	neuropathy	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	DPN	_	_	NNP	_	_	_	_	_
15	after	_	_	IN	_	_	_	_	_
16	they	_	_	PRP	_	_	_	_	_
17	were	_	_	VBD	_	_	_	_	_
18	treated	_	_	VBN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	pancreas	_	_	NN	_	_	_	_	_
22	transplant	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	discrepancies	_	_	NNS	_	_	_	_	_
4	exist	_	_	VBP	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	time	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	response	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Pharmacological	_	_	JJ	_	_	_	_	_
2	treatment	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	used	_	_	VBN	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	painful	_	_	JJ	_	_	_	_	_
7	DPN	_	_	NN	_	_	_	_	_
8	manifested	_	_	VBN	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	numbness	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	burning	_	_	VBG	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	stabbing	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	or	_	_	CC	_	_	_	_	_
17	excruciating	_	_	JJ	_	_	_	_	_
18	or	_	_	CC	_	_	_	_	_
19	intractable	_	_	JJ	_	_	_	_	_
20	pain	_	_	NN	_	_	_	_	_
21	;	_	_	:	_	_	_	_	_
22	only	_	_	RB	_	_	_	_	_
23	three	_	_	CD	_	_	_	_	_
24	treatments	_	_	NNS	_	_	_	_	_
25	are	_	_	VBP	_	_	_	_	_
26	approved	_	_	VBN	_	_	_	_	_
27	by	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	U.S.	_	_	NNP	_	_	_	_	_
30	Food	_	_	NNP	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	Drug	_	_	NNP	_	_	_	_	_
33	Administration	_	_	NNP	_	_	_	_	_
34	for	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	pain	_	_	NN	_	_	_	_	_
37	associated	_	_	VBN	_	_	_	_	_
38	with	_	_	IN	_	_	_	_	_
39	DPN	_	_	NN	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	namely	_	_	RB	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	pregabalin	_	_	NN	_	_	_	_	_
44	,	_	_	,	_	_	_	_	_
45	tapentadol	_	_	NN	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	and	_	_	CC	_	_	_	_	_
48	duloxetine	_	_	NN	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	pharmacological	_	_	JJ	_	_	_	_	_
3	therapy	_	_	NN	_	_	_	_	_
4	includes	_	_	VBZ	_	_	_	_	_
5	analgesics	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	such	_	_	JJ	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	tramadol	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	acetaminophen	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	some	_	_	DT	_	_	_	_	_
15	opioids	_	_	NNS	_	_	_	_	_
16	such	_	_	JJ	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	oxycodone	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	which	_	_	WDT	_	_	_	_	_
21	have	_	_	VBP	_	_	_	_	_
22	constipation	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	nausea	_	_	NN	_	_	_	_	_
25	as	_	_	IN	_	_	_	_	_
26	side	_	_	NN	_	_	_	_	_
27	effects	_	_	NNS	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	must	_	_	MD	_	_	_	_	_
31	be	_	_	VB	_	_	_	_	_
32	taken	_	_	VBN	_	_	_	_	_
33	with	_	_	IN	_	_	_	_	_
34	care	_	_	NN	_	_	_	_	_
35	because	_	_	IN	_	_	_	_	_
36	they	_	_	PRP	_	_	_	_	_
37	can	_	_	MD	_	_	_	_	_
38	be	_	_	VB	_	_	_	_	_
39	misused	_	_	VBN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Therapy	_	_	NN	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	antidepressants	_	_	NNS	_	_	_	_	_
4	such	_	_	JJ	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	amitriptyline	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	nortriptyline	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	venlafaxine	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	among	_	_	IN	_	_	_	_	_
14	others	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	has	_	_	VBZ	_	_	_	_	_
17	shown	_	_	VBN	_	_	_	_	_
18	an	_	_	DT	_	_	_	_	_
19	efficacy	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	neuropathic	_	_	JJ	_	_	_	_	_
22	pain	_	_	NN	_	_	_	_	_
23	management	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	effect	_	_	NN	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	recapture	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	noradrenaline	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	serotonin	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	as	_	_	RB	_	_	_	_	_
14	well	_	_	RB	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	on	_	_	IN	_	_	_	_	_
17	muscarinic	_	_	JJ	_	_	_	_	_
18	effects	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	spite	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	there	_	_	EX	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	limited	_	_	JJ	_	_	_	_	_
9	studies	_	_	NNS	_	_	_	_	_
10	evaluating	_	_	VBG	_	_	_	_	_
11	these	_	_	DT	_	_	_	_	_
12	drugs	_	_	NNS	_	_	_	_	_
13	because	_	_	IN	_	_	_	_	_
14	their	_	_	PRP$	_	_	_	_	_
15	doses	_	_	NNS	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	clinical	_	_	JJ	_	_	_	_	_
18	trials	_	_	NNS	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	not	_	_	RB	_	_	_	_	_
21	entirely	_	_	RB	_	_	_	_	_
22	reproducible	_	_	JJ	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	clinical	_	_	JJ	_	_	_	_	_
25	practice	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Alpha-lipoic	_	_	JJ	_	_	_	_	_
2	acid	_	_	NN	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	ALA	_	_	NNP	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	has	_	_	VBZ	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	suggested	_	_	VBN	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	potential	_	_	JJ	_	_	_	_	_
12	therapeutic	_	_	JJ	_	_	_	_	_
13	agent	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	treating	_	_	VBG	_	_	_	_	_
16	DPN	_	_	NN	_	_	_	_	_
17	;	_	_	:	_	_	_	_	_
18	its	_	_	PRP$	_	_	_	_	_
19	antioxidant	_	_	JJ	_	_	_	_	_
20	capacity	_	_	NN	_	_	_	_	_
21	seems	_	_	VBZ	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	delay	_	_	VB	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	reverse	_	_	VB	_	_	_	_	_
26	damages	_	_	NNS	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	peripheral	_	_	JJ	_	_	_	_	_
29	nerves	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	human	_	_	JJ	_	_	_	_	_
3	randomized	_	_	VBN	_	_	_	_	_
4	controlled	_	_	VBN	_	_	_	_	_
5	trials	_	_	NNS	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	RCTs	_	_	NNS	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_
9	have	_	_	VBP	_	_	_	_	_
10	investigated	_	_	VBN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	effects	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	ALA	_	_	NNP	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	development	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	diabetic	_	_	JJ	_	_	_	_	_
20	nephropathy	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	meta-analysis	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	four	_	_	CD	_	_	_	_	_
5	RCTs	_	_	NNS	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	n	_	_	NN	_	_	_	_	_
8	=	_	_	SYM	_	_	_	_	_
9	653	_	_	CD	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	showed	_	_	VBD	_	_	_	_	_
12	that	_	_	IN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	compared	_	_	VBN	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	placebo	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	intravenous	_	_	JJ	_	_	_	_	_
19	ALA	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	600	_	_	CD	_	_	_	_	_
22	mg	_	_	NN	_	_	_	_	_
23	per	_	_	IN	_	_	_	_	_
24	day	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	decreased	_	_	VBD	_	_	_	_	_
27	symptoms	_	_	NNS	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	neuropathy	_	_	NN	_	_	_	_	_
30	when	_	_	WRB	_	_	_	_	_
31	administered	_	_	VBN	_	_	_	_	_
32	for	_	_	IN	_	_	_	_	_
33	three	_	_	CD	_	_	_	_	_
34	weeks	_	_	NNS	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	but	_	_	CC	_	_	_	_	_
37	symptom	_	_	NN	_	_	_	_	_
38	improvement	_	_	NN	_	_	_	_	_
39	with	_	_	IN	_	_	_	_	_
40	oral	_	_	JJ	_	_	_	_	_
41	ALA	_	_	NN	_	_	_	_	_
42	(	_	_	-LRB-	_	_	_	_	_
43	>600	_	_	CD	_	_	_	_	_
44	mg	_	_	NN	_	_	_	_	_
45	per	_	_	IN	_	_	_	_	_
46	day	_	_	NN	_	_	_	_	_
47	for	_	_	IN	_	_	_	_	_
48	3	_	_	CD	_	_	_	_	_
49	–	_	_	TO	_	_	_	_	_
50	5	_	_	CD	_	_	_	_	_
51	weeks	_	_	NNS	_	_	_	_	_
52	)	_	_	-RRB-	_	_	_	_	_
53	was	_	_	VBD	_	_	_	_	_
54	not	_	_	RB	_	_	_	_	_
55	clinically	_	_	RB	_	_	_	_	_
56	significant	_	_	JJ	_	_	_	_	_
57	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	no	_	_	DT	_	_	_	_	_
4	evidence	_	_	NN	_	_	_	_	_
5	evaluating	_	_	VBG	_	_	_	_	_
6	long-term	_	_	JJ	_	_	_	_	_
7	treatment	_	_	NN	_	_	_	_	_
8	.	_	_	.	_	_	_	_	_


1	Currently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	treatments	_	_	NNS	_	_	_	_	_
4	based	_	_	VBN	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	use	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	mesenchymal	_	_	JJ	_	_	_	_	_
10	stem	_	_	NN	_	_	_	_	_
11	cells	_	_	NNS	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	MSC	_	_	NNP	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	derived	_	_	VBN	_	_	_	_	_
16	from	_	_	IN	_	_	_	_	_
17	adipose	_	_	NN	_	_	_	_	_
18	tissue	_	_	NN	_	_	_	_	_
19	have	_	_	VBP	_	_	_	_	_
20	been	_	_	VBN	_	_	_	_	_
21	considered	_	_	VBN	_	_	_	_	_
22	as	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	potential	_	_	JJ	_	_	_	_	_
25	treatment	_	_	NN	_	_	_	_	_
26	against	_	_	IN	_	_	_	_	_
27	DPN	_	_	NNP	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	therapies	_	_	NNS	_	_	_	_	_
3	promote	_	_	VBP	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	production	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	pro-angiogenic	_	_	JJ	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	neuroprotective	_	_	JJ	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	anti-inflammatory	_	_	JJ	_	_	_	_	_
13	factors	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	which	_	_	WDT	_	_	_	_	_
16	have	_	_	VBP	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	positive	_	_	JJ	_	_	_	_	_
19	impact	_	_	NN	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	clinical	_	_	JJ	_	_	_	_	_
23	manifestations	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	disease	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	other	_	_	JJ	_	_	_	_	_
4	hand	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	use	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	biological	_	_	JJ	_	_	_	_	_
10	therapy	_	_	NN	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	low	_	_	JJ	_	_	_	_	_
13	doses	_	_	NNS	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	IL-6	_	_	NNP	_	_	_	_	_
16	has	_	_	VBZ	_	_	_	_	_
17	been	_	_	VBN	_	_	_	_	_
18	demonstrated	_	_	VBN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	promote	_	_	VB	_	_	_	_	_
21	improvement	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	blood	_	_	NN	_	_	_	_	_
24	flow	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	decrease	_	_	VB	_	_	_	_	_
27	chronic	_	_	JJ	_	_	_	_	_
28	inflammation	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	regenerate	_	_	VB	_	_	_	_	_
32	peripheral	_	_	JJ	_	_	_	_	_
33	nerve	_	_	NN	_	_	_	_	_
34	fibers	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Accordingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	IL-6	_	_	NNP	_	_	_	_	_
4	may	_	_	MD	_	_	_	_	_
5	prove	_	_	VB	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	effective	_	_	JJ	_	_	_	_	_
10	treatment	_	_	NN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	protection	_	_	NN	_	_	_	_	_
14	and/or	_	_	NN	_	_	_	_	_
15	restoration	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	peripheral	_	_	JJ	_	_	_	_	_
18	nerve	_	_	NN	_	_	_	_	_
19	function	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	DPN	_	_	NN	_	_	_	_	_
22	;	_	_	:	_	_	_	_	_
23	see	_	_	VB	_	_	_	_	_
24	Table	_	_	NNP	_	_	_	_	_
25	1	_	_	CD	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	4.2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Treatments	_	_	NNS	_	_	_	_	_
2	for	_	_	IN	_	_	_	_	_
3	Peripheral	_	_	JJ	_	_	_	_	_
4	Arterial	_	_	JJ	_	_	_	_	_
5	Disease	_	_	NN	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	Ischemia	_	_	NN	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_


1	Ischemia	_	_	NN	_	_	_	_	_
2	presenting	_	_	VBG	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	diabetic	_	_	JJ	_	_	_	_	_
5	patients	_	_	NNS	_	_	_	_	_
6	due	_	_	JJ	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	reduction	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	blood	_	_	NN	_	_	_	_	_
12	flow	_	_	NN	_	_	_	_	_
13	that	_	_	WDT	_	_	_	_	_
14	occurs	_	_	VBZ	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	both	_	_	DT	_	_	_	_	_
17	small	_	_	JJ	_	_	_	_	_
18	vessels	_	_	NNS	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	microvascular	_	_	JJ	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	such	_	_	JJ	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	capillaries	_	_	NNS	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	large	_	_	JJ	_	_	_	_	_
28	vessels	_	_	NNS	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	macrovascular	_	_	JJ	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	such	_	_	JJ	_	_	_	_	_
33	as	_	_	IN	_	_	_	_	_
34	arteries	_	_	NNS	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	veins	_	_	NNS	_	_	_	_	_
37	)	_	_	-RRB-	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	or	_	_	CC	_	_	_	_	_
40	due	_	_	JJ	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	a	_	_	DT	_	_	_	_	_
43	decrease	_	_	NN	_	_	_	_	_
44	of	_	_	IN	_	_	_	_	_
45	angiogenesis	_	_	NN	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	can	_	_	MD	_	_	_	_	_
48	be	_	_	VB	_	_	_	_	_
49	treated	_	_	VBN	_	_	_	_	_
50	through	_	_	IN	_	_	_	_	_
51	revascularization	_	_	NN	_	_	_	_	_
52	of	_	_	IN	_	_	_	_	_
53	at	_	_	IN	_	_	_	_	_
54	least	_	_	JJS	_	_	_	_	_
55	one	_	_	CD	_	_	_	_	_
56	of	_	_	IN	_	_	_	_	_
57	the	_	_	DT	_	_	_	_	_
58	foot	_	_	NN	_	_	_	_	_
59	arteries	_	_	NNS	_	_	_	_	_
60	to	_	_	TO	_	_	_	_	_
61	try	_	_	VB	_	_	_	_	_
62	to	_	_	TO	_	_	_	_	_
63	restore	_	_	VB	_	_	_	_	_
64	blood	_	_	NN	_	_	_	_	_
65	flow	_	_	NN	_	_	_	_	_
66	in	_	_	IN	_	_	_	_	_
67	patients	_	_	NNS	_	_	_	_	_
68	with	_	_	IN	_	_	_	_	_
69	a	_	_	DT	_	_	_	_	_
70	DFU	_	_	NN	_	_	_	_	_
71	whose	_	_	WP$	_	_	_	_	_
72	toe	_	_	NN	_	_	_	_	_
73	pressure	_	_	NN	_	_	_	_	_
74	is	_	_	VBZ	_	_	_	_	_
75	<30	_	_	CD	_	_	_	_	_
76	mmHg	_	_	NN	_	_	_	_	_
77	or	_	_	CC	_	_	_	_	_
78	transcutaneous	_	_	JJ	_	_	_	_	_
79	oxygen	_	_	NN	_	_	_	_	_
80	pressure	_	_	NN	_	_	_	_	_
81	(	_	_	-LRB-	_	_	_	_	_
82	TcPO2	_	_	NN	_	_	_	_	_
83	)	_	_	-RRB-	_	_	_	_	_
84	<25	_	_	CD	_	_	_	_	_
85	mmHg	_	_	NN	_	_	_	_	_
86	,	_	_	,	_	_	_	_	_
87	as	_	_	RB	_	_	_	_	_
88	well	_	_	RB	_	_	_	_	_
89	as	_	_	IN	_	_	_	_	_
90	in	_	_	IN	_	_	_	_	_
91	those	_	_	DT	_	_	_	_	_
92	who	_	_	WP	_	_	_	_	_
93	have	_	_	VBP	_	_	_	_	_
94	a	_	_	DT	_	_	_	_	_
95	DFU	_	_	NN	_	_	_	_	_
96	that	_	_	WDT	_	_	_	_	_
97	does	_	_	VBZ	_	_	_	_	_
98	not	_	_	RB	_	_	_	_	_
99	heal	_	_	VB	_	_	_	_	_
100	with	_	_	IN	_	_	_	_	_
101	pressure	_	_	NN	_	_	_	_	_
102	on	_	_	IN	_	_	_	_	_
103	the	_	_	DT	_	_	_	_	_
104	ankle	_	_	NN	_	_	_	_	_
105	of	_	_	IN	_	_	_	_	_
106	<50	_	_	CD	_	_	_	_	_
107	mmHg	_	_	NN	_	_	_	_	_
108	or	_	_	CC	_	_	_	_	_
109	ankle-brachial	_	_	JJ	_	_	_	_	_
110	index	_	_	NN	_	_	_	_	_
111	(	_	_	-LRB-	_	_	_	_	_
112	ABI	_	_	NNP	_	_	_	_	_
113	)	_	_	-RRB-	_	_	_	_	_
114	<0.5	_	_	CD	_	_	_	_	_
115	.	_	_	.	_	_	_	_	_

